Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 10Recurrence 2Neoplasms, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

Dexamethasone 5Trimethoprim, Sulfamethoxazole Drug Combination 4gamma-Globulins 3Lenalidomide 3Ciprofloxacin 3Bortezomib 3pomalidomide 2fludarabine phosphate 2fludarabine 2elotuzumab 2carfilzomib 2Radiotherapy 2Immunoglobulins, Intravenous 2Cyclophosphamide 2Amoxicillin-Potassium Clavulanate Combination 2siltuximab 1selinexor 1nirogacestat 1iberdomide 1daratumumab 1belantamab mafodotin 1Positron-Emission Tomography 1Melphalan 1Interviews as Topic 1Immunoglobulins 1Focus Groups 1Fecal Microbiota Transplantation 1Clonal Hematopoiesis 1Clavulanic Acid 1Chromatin Immunoprecipitation Sequencing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms, Plasma Cell × belantamab mafodotin × Clear all
NCT05055063 2026-06-01

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

M.D. Anderson Cancer Center

Phase 1 Recruiting
30 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡